Prodrug enzymes and their applications in image-guided therapy of cancer: Tracking prodrug enzymes to minimize collateral damage

Drug Delivery and Translational Research

Volumn 2, Issue 1, 2012, Pages 22-30

  Penet, Marie France ^a   Chen, Zhihang ^a   Li, Cong ^a   Winnard, Paul T ^a   Bhujwalla, Zaver M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer; Imaging; Prodrug enzymes

Indexed keywords

CARBOXYLESTERASE; CARBOXYPEPTIDASE; CYTOSINE DEAMINASE; DEOXYCYTIDINE KINASE; FLOXURIDINE; FLUCYTOSINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; NITROREDUCTASE; ONCOLYTIC ADENOVIRUS; PRODRUG; THYMIDINE KINASE; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER THERAPY; COMPUTER ASSISTED DRUG THERAPY; CYTOTOXICITY; DRUG EFFICACY; ENZYME LOCALIZATION; ENZYME PRODRUG THERAPY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; HUMAN; IMAGE GUIDED DRUG THERAPY; IMAGING; ISOTOPE LABELING; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PANCREAS CANCER; POLYMER DIRECTED ENZYME PRODRUG THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REPORTER GENE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84865455240     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-011-0052-0     Document Type: Review

References (36)

1. Xu G, et al. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res. 2001;7(11):3314-24.
2. Mahato R, et al. Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev. 2011;63(8):659-70. PMCID: 3132824.
3. Sharma SK, et al. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin Cancer Res. 2005;11(2 Pt 1):814-25.
4. Bhatia J, et al. Catalytic activity of an in vivo tumor targeted anti- CEA scFv::carboxypeptidase G2 fusion protein. Int J Cancer. 2000;85(4):571-7.
5. Longley DB, et al. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3(5):330-8.
6. Aboagye EO, et al. Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging. Cancer Res. 1998;58(18):4075-8.
7. Hamstra DA, et al. The use of 19F spectroscopy and diffusionweighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther. 2004;10(5):916-28.
8. Wright CM, et al. A protein therapeutic modality founded on molecular regulation. Proc Natl Acad Sci U S A. 2011;108 (39):16206-11. PMCID: 3182702.
9. Crystal RG, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5- fluorocytosine. Hum Gene Ther. 1997;8(8):985-1001.
10. Pandha HS, et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol. 1999;17(7):2180-9.
11. Li C, et al. Image-guided enzyme/prodrug cancer therapy. Clin Cancer Res. 2008;14(2):515-22.
12. Li C, et al. Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. ACS Nano. 2010;4(11):6707-16.
13. Xing L, et al. Non-invasive molecular and functional imaging of cytosine deaminase and uracil phosphoribosyltransferase fused with red fluorescence protein. Acta Oncol. 2008;47(7):1211-20.
14. Blasberg RG, et al. Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Q J Nucl Med. 1999;43(2):163-9.
15. Yaghoubi SS, et al. Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography. Cancer Gene Ther. 2005;12(3):329-39.
16. Schipper ML, et al. Evaluation of herpes simplex virus 1 thymidine kinase-mediated trapping of (131)I FIAU and prodrug activation of ganciclovir as a synergistic cancer radio/chemotherapy. Mol Imaging Biol. 2007;9(3):110-6.
17. Miyagawa T, et al. Imaging of HSV-tk Reporter gene expression: comparison between [18F]FEAU, [18F]FFEAU, and other imaging probes. J Nucl Med. 2008;49(4):637-48.
18. Abate-Daga D, et al. Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing. PLoS One. 2011;6 (10):e26142. PMCID: 3196510.
19. Tseng JC, et al. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J Nucl Med. 2006;47 (7):1136-43.
20. Penuelas I, et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology. 2005;128(7):1787-95.
21. Jacobs AH, et al. Imaging-guided gene therapy of experimental gliomas. Cancer Res. 2007;67(4):1706-15.
22. Chandran SS, et al. A prostate-specific antigen activated N-(2- hydroxypropyl) methacrylamide copolymer prodrug as dualtargeted therapy for prostate cancer. Mol Cancer Ther. 2007;6 (11):2928-37.
23. LeBeau AM, et al. Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer. Bioorg Med Chem. 2009;17(14):4888-93. PMCID: 3087300.
24. Chuang CH, et al. In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a non-inhibitory protease substrate. Clin Cancer Res. 2011. doi:10.1158/1078-0432.CCR-11-0608.
25. Rowsell S, et al. Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy. Structure. 1997;5(3):337-47.
26. Jamin Y, et al. Noninvasive detection of carboxypeptidase G2 activity in vivo. NMR Biomed. 2011;24(4):343-50.
27. Hedley D, et al. Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury. Nat Rev Cancer. 2007;7(11):870-9.
28. Jamin Y, et al. Hyperpolarized (13)C magnetic resonance detection of carboxypeptidase G2 activity. Magn Reson Med. 2009;62 (5):1300-4.
29. Lim SH, et al. Therapeutic targeting of subdural medulloblastomas using human neural stem cells expressing carboxylesterase. Cancer Gene Ther. 2011;18(11):817-24.
30. Shu CJ, et al. Novel PET probes specific for deoxycytidine kinase. J Nucl Med. 2010;51(7):1092-8. PMCID: 3119947.
31. Likar Y, et al. A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. J Nucl Med. 2010;51(9):1395-403.
32. Bhaumik S, et al. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals. Gene Therapy. 2011. doi:10.1038/gt.2011.101.
33. Patel P, et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Molecular Therapy. 2009;17(7):1292-9. PMCID: 2835198.
34. Van Rite BD, et al. Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine. Cancer Lett. 2011;307(1):53-61.
35. Tietze LF, et al. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT. Curr Pharm Des. 2011;17(32):3527-47.
36. Goel S, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071-121.